Skip to content

ORGO Stock Surges, Here’s Why…

Regenerative medicine company Organogenesis Holdings (NASDAQ: ORGO) shares have jumped premarket after the company reported its preliminary third-quarter 2020 financial results shortly after the closing bell on Wednesday. 

The company reported that it expects third-quarter revenue of between $99 and $100 million, up between 54% to 56% for the three months ending the 30th of September. 

ORGO also said that the company expects to report a positive GAAP net income and a positive adjusted EBITDA for the period. 

The company also upgraded its full-year 2020 guidance. ORGO said that it now expects net revenue of between $311 to $314 million compared to the previously forecasted $261 million with its primary revenue driver being its advanced wound care products.  

ORGO went on to state that it expects to report a positive GAAP net income and adjusted EBITDA for both the fourth quarter and the fiscal full-year period. 

After-hours trading has seen the company’s stock price jump almost 39% higher to $5.25 per share after the previous days close at $3.78.

PEOPLE WHO READ THIS ALSO VIEWED:

Sam Boughedda
Sam Boughedda
Team Member

Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples. 

Stay ahead of the markets

Sign up to our free Morning Markets email, every weekday before the open.